Risks and Indications of Phenylbutazone: Another Look
- 2 January 1987
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 7 (1) , 25-27
- https://doi.org/10.1002/j.1875-9114.1987.tb03502.x
Abstract
In 1984 an extensive review of phenylbutazone risks was undertaken by the Food and Drug Administration (FDA). Since that review, new recommendations for the drug's use have been published. Marketed in 1952, phenylbutazone has long been recognized as capable of inducing aplastic anemia. The risk of marrow depression is greatest in elderly females treated for over a month. Overall, the risk does not exceed that of many commonly used drugs (e.g., penicillin, which induces anaphylaxis). Nonetheless, phenylbutazone should not be a drug of first choice and should not be used for minor, self-limited conditions.Keywords
This publication has 8 references indexed in Scilit:
- Risks of Agranulocytosis and Aplastic AnemiaPublished by American Medical Association (AMA) ,1986
- Analgesic Risks and PharmacoepidemiologyPublished by American Medical Association (AMA) ,1986
- Adverse-Drug-Reaction MonitoringNew England Journal of Medicine, 1986
- Drug-Induced Blood DisordersJAMA, 1984
- Phenylbutazone, musculoskeletal disease, and leukemiaJournal of Chronic Diseases, 1982
- Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone.BMJ, 1977
- Aspirin Use in Patients with Major Upper Gastrointestinal Bleeding and Peptic-Ulcer DiseaseNew England Journal of Medicine, 1974
- Drug-induced Blood Dyscrasias in SwedenBMJ, 1973